Latest Insider Transactions at Dexcom Inc (DXCM)
This section provides a real-time view of insider transactions for Dexcom Inc (DXCM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of DEXCOM INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of DEXCOM INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 24
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.29%
|
$374,413
$347.75 P/Share
|
|
May 24
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
600
-3.97%
|
$207,600
$346.74 P/Share
|
|
May 21
2021
|
Steven R Altman Director |
BUY
Grant, award, or other acquisition
|
Direct |
910
+50.0%
|
-
|
|
May 21
2021
|
Nicholas Augustinos Director |
BUY
Grant, award, or other acquisition
|
Direct |
918
+18.99%
|
-
|
|
May 21
2021
|
Richard Alexander Collins Director |
BUY
Grant, award, or other acquisition
|
Direct |
910
+50.0%
|
-
|
|
May 21
2021
|
Karen M Dahut Director |
BUY
Grant, award, or other acquisition
|
Direct |
918
+30.64%
|
-
|
|
May 21
2021
|
Mark G Foletta Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,054
+50.0%
|
-
|
|
May 21
2021
|
Bridgette P Heller Director |
BUY
Grant, award, or other acquisition
|
Direct |
919
+17.39%
|
-
|
|
May 21
2021
|
Barbara Kahn Director |
BUY
Grant, award, or other acquisition
|
Direct |
918
+50.0%
|
-
|
|
May 21
2021
|
Kyle Malady Director |
BUY
Grant, award, or other acquisition
|
Direct |
910
+29.43%
|
-
|
|
May 21
2021
|
Jay S Skyler Director |
BUY
Grant, award, or other acquisition
|
Direct |
900
+50.0%
|
-
|
|
May 21
2021
|
Eric Topol Director |
BUY
Grant, award, or other acquisition
|
Direct |
919
+50.0%
|
-
|
|
May 20
2021
|
Steven R Altman Director |
BUY
Other acquisition or disposition
|
Indirect |
806
+5.52%
|
-
|
|
May 20
2021
|
Steven R Altman Director |
SELL
Other acquisition or disposition
|
Direct |
806
-100.0%
|
-
|
|
May 20
2021
|
Richard Alexander Collins Director |
BUY
Other acquisition or disposition
|
Indirect |
787
+8.29%
|
-
|
|
May 20
2021
|
Richard Alexander Collins Director |
SELL
Other acquisition or disposition
|
Direct |
787
-100.0%
|
-
|
|
May 20
2021
|
Mark G Foletta Director |
BUY
Other acquisition or disposition
|
Indirect |
895
+5.97%
|
-
|
|
May 20
2021
|
Mark G Foletta Director |
SELL
Other acquisition or disposition
|
Direct |
895
-100.0%
|
-
|
|
May 20
2021
|
Barbara Kahn Director |
BUY
Other acquisition or disposition
|
Indirect |
787
+9.31%
|
-
|
|
May 20
2021
|
Barbara Kahn Director |
SELL
Other acquisition or disposition
|
Direct |
787
-100.0%
|
-
|
|
May 20
2021
|
Jay S Skyler Director |
BUY
Other acquisition or disposition
|
Indirect |
822
+2.36%
|
-
|
|
May 20
2021
|
Jay S Skyler Director |
SELL
Other acquisition or disposition
|
Direct |
822
-100.0%
|
-
|
|
May 20
2021
|
Eric Topol Director |
BUY
Other acquisition or disposition
|
Indirect |
833
+0.9%
|
-
|
|
May 20
2021
|
Eric Topol Director |
SELL
Other acquisition or disposition
|
Direct |
833
-100.0%
|
-
|
|
May 03
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
5,535
-0.72%
|
$2,103,300
$380.53 P/Share
|
|
Apr 26
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.53%
|
$207,500
$415.83 P/Share
|
|
Apr 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.66%
|
$442,390
$410.2 P/Share
|
|
Apr 15
2021
|
Paul R Flynn EVP Global Revenue |
SELL
Open market or private sale
|
Direct |
758
-5.8%
|
$303,200
$400.0 P/Share
|
|
Apr 05
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
6,221
-1.79%
|
$2,276,886
$366.64 P/Share
|
|
Mar 26
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.47%
|
$175,000
$350.0 P/Share
|
|
Mar 23
2021
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Indirect |
1,109
-2.99%
|
$398,131
$359.03 P/Share
|
|
Mar 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.39%
|
$386,282
$358.91 P/Share
|
|
Mar 18
2021
|
Nicholas Augustinos Director |
SELL
Other acquisition or disposition
|
Indirect |
2,192
-21.72%
|
-
|
|
Mar 18
2021
|
Nicholas Augustinos Director |
BUY
Other acquisition or disposition
|
Direct |
2,192
+42.24%
|
-
|
|
Mar 11
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
1,867
-10.37%
|
$662,785
$355.86 P/Share
|
|
Mar 10
2021
|
Donald Abbey EVP Global Business Services I |
SELL
Open market or private sale
|
Direct |
5,566
-10.03%
|
$2,014,892
$362.92 P/Share
|
|
Mar 10
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Open market or private sale
|
Direct |
5,566
-13.62%
|
$2,014,892
$362.92 P/Share
|
|
Mar 10
2021
|
Quentin S. Blackford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,509
-12.6%
|
$2,356,258
$362.22 P/Share
|
|
Mar 10
2021
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,353
-4.83%
|
$1,937,786
$362.92 P/Share
|
|
Mar 10
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,471
-14.64%
|
$1,256,502
$362.92 P/Share
|
|
Mar 10
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
5,566
-9.11%
|
$2,014,892
$362.92 P/Share
|
|
Mar 10
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
14,044
-10.68%
|
$5,083,928
$362.92 P/Share
|
|
Mar 10
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
2,700
-13.04%
|
$977,400
$362.92 P/Share
|
|
Mar 10
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
941
-5.86%
|
$340,642
$362.92 P/Share
|
|
Mar 09
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
3,857
-0.41%
|
$1,388,520
$360.86 P/Share
|
|
Mar 09
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
152
-0.73%
|
$54,112
$356.94 P/Share
|
|
Mar 08
2021
|
Donald Abbey EVP Global Business Services I |
BUY
Grant, award, or other acquisition
|
Direct |
5,301
+8.72%
|
-
|
|
Mar 08
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
BUY
Grant, award, or other acquisition
|
Direct |
5,301
+11.48%
|
-
|
|
Mar 08
2021
|
Quentin S. Blackford Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,491
+12.66%
|
-
|
|
Mar 08
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,634
+19.2%
|
-
|